Cargando…
Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine
OBJECTIVE: MAP0004 is an investigational product which delivers dihydroergotamine (DHE) through the lung via a breath-synchronized metered dose inhaler. The objective of this study was to compare the acute effects of orally inhaled and intravenous (IV) DHE to placebo on maximum change and area under...
Autores principales: | Noveck, Robert J, Douglas, Pamela S, Chow, Shein-Chung, Mangum, Barry, Kori, Shashidhar, Kellerman, Donald J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728267/ https://www.ncbi.nlm.nih.gov/pubmed/23926420 http://dx.doi.org/10.2147/DDDT.S44093 |
Ejemplares similares
-
Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
por: Kori, S, et al.
Publicado: (2013) -
Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
por: Bérard, Anick, et al.
Publicado: (2021) -
Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016) -
Dihydroergotamine (DHE) – Then and Now: A Narrative Review
por: Silberstein, Stephen D., et al.
Publicado: (2019) -
Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)